Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2019
Value assessment on anti-cancer drugs hotly discussed
24 October 2019 - Experts are raising the need to establish tools to calculate the value of new anticancer medicines ...
Posted by Michael Wonder on 14 Oct 2019
Sanofi to cover part of Dupixent cost for atopic dermatitis patients
11 October 2019 - Sanofi said it would run a program to support part of the cost of Dupixent, a ...
Posted by Michael Wonder on 02 Oct 2019
CDK4/6 inhibitor+fulvestrant combo nears getting benefit
2 October 2019 - The combination therapy of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor and fulvestrant for advanced or metastatic ...
Posted by Michael Wonder on 25 Sep 2019
'Xtandi emerges as convenient treatment option for prostate cancer patients'
25 September 2019 - Astellas Korea is strengthening its position in the local prostate cancer market with Xtandi, a hormone therapy ...
Posted by Michael Wonder on 16 Sep 2019
Lenvima to get benefit as first-line treatment of hepatocellular carcinoma
16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...
Posted by Michael Wonder on 27 Aug 2019
Pharmacists demand audit over Gliatilin’s insurance benefit
27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...
Posted by Michael Wonder on 06 Aug 2019
Health ministry to reimburse Novartis’ Revolade treating severe aplastic anaemia
1 August 2019 - Novartis Korea’s Revolade (eltrombopag olamine) will receive reimbursement for treating people with severe aplastic anaemia who ...
Posted by Michael Wonder on 29 Jul 2019
Takeda’s Zejula poised to change local ovarian cancer treatment market
29 July 2019 - Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance benefit, according to the Health Insurance Review and ...
Posted by Michael Wonder on 27 Jul 2019
Pfizer's Besponsa, Takeda's Zejula likely to get insurance coverage
26 July 2019 - Pfizer's Besponsa, a B-cell lymphoblastic leukaemia treatment, and Takeda's Zejula, an ovarian cancer treatment, have passed ...
Posted by Michael Wonder on 18 Jul 2019
Two cancer immunotherapy makers face different situations in reimbursement talks
18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...
Posted by Michael Wonder on 03 Jul 2019
Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz
1 July 2019 - The Korean branch of Eli Lilly said that it had gained additional reimbursement for its psoriasis ...
Posted by Michael Wonder on 22 Jun 2019
Delayed patient access to innovative medical technologies in South Korea: a lead-time analysis of reimbursement coverage determinations
20 June 2019 - Timely access to innovative medical technologies driven by accelerated patient access pathways can substantially improve the health ...
Posted by Michael Wonder on 13 Jun 2019
Role of health technology assessment in drug policies: Korea
13 June 2019 - South Korea is the first Asian country to mandate the submission of pharmacoeconomic data for reimbursement decision ...
Posted by Michael Wonder on 13 Jun 2019
Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific Region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea
13 June 2019 - Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of ...
Posted by Michael Wonder on 13 Jun 2019
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug
12 June 2019 - Korean patients with severe atopic dermatitis gathered in front of the National Assembly on Tuesday to ...